Introduction
============

Pathological left ventricular hypertrophy (LVH) is a hallmark feature of a number cardiovascular diseases ([@B25]; [@B41]; [@B42]) and is strongly associated with increased risk of developing heart failure (HF; [@B27]). In response to stress, such as hypertension and pressure overload, several cellular and sub-cellular modifications lead to cardiac remodeling ([@B35]; [@B8]). Despite the critical role of LVH in the development of cardiac dysfunction, the mechanisms underlying cardiomyocyte hypertrophy in response to pressure overload still remain not completely understood.

Members of a family of cyclic adenosine monophosphate (cAMP)-dependent protein kinase A (PKA) anchor proteins (AKAPs) have been identified as potential regulators of cardiac responses to pathological stimuli including pressure overload-induced LVH ([@B33]; [@B16]; [@B37]). By anchoring PKA to membranes and cellular organelles, AKAPs play a key role in the intracellular propagation of cAMP/PKA signals ([@B20]; [@B11]). Several AKAPs are expressed in cardiomyocytes, regulating crucial cellular functions ([@B16]). Among these, mAKAP has been shown to regulate hypertrophy of neonatal cardiomyocytes through mitogen-activated protein kinases (MAPKs) signaling pathways ([@B37]). Moreover, AKAP-Lbc also regulates cardiomyocytes hypertrophy forming a complex with other protein kinases ([@B12]).

Mitochondria are the major energy source for contraction and relaxation in cardiomyocytes. LVH and ultimately HF are characterized by mitochondrial dysfunction leading to reduced ATP production and increased generation of mitochondrial reactive oxygen species (ROS; [@B44]). A sub-family of AKAPs deriving from the alternative splicing of the *Akap1* gene amplifies signals to mitochondria (mitoAKAPs), and has been shown to be critical under several pathological conditions ([@B10]; [@B33]; [@B43]; [@B40]). We have previously demonstrated that the absence of *Akap1* exacerbates cardiac injury following myocardial infarction in mice, promoting mitochondrial dysfunction, enhancing ROS production and infarct size, and ultimately reducing survival ([@B40]). Using a rat model of LVH, we have shown that degradation of AKAP121, the most abundant *Akap1* product in muscle cells, occurs early in response to pressure overload, and is associated with impaired mitochondrial function and reduced cell survival ([@B33]). Degradation of AKAP121 is mediated, in part, by the E3 ubiquitin ligase seven *in absentia* homolog 2 (*Siah2*; [@B10]). Previous studies in our laboratory and others have also shown that AKAP121 degradation upon ischemia is reduced in *Siah2* knockout mice (*Siah2*^-/-^; [@B26]; [@B40]), and that *Siah2* deletion reduces cardiac susceptibility to ischemia due to loss of *Akap1* ([@B40]). Although the potential role of AKAP121 in the hypertrophic growth of cardiomyocytes has been suggested by *in vitro* studies ([@B1]), basal cardiac mass, structure, and function of *Akap1*^-/-^ mice were not significantly different compared to their *wt* littermates. Thus, whether *Akap1* plays a causal role during the development of LVH *in vivo* remains unknown. In the present investigation, we hypothesized that loss of *Akap1* exacerbates cardiac hypertrophy in response to pressure overload, leading to an accelerated progression toward HF.

Materials and Methods {#s1}
=====================

Experimental Animals
--------------------

All experiments involving animals in this study were conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication 8th edition, update 2011), and were approved by the animal welfare regulation of University of Naples Federico II, Naples, Italy, and by the Ministry of Health, Italy. *Akap*1 knockout mice (*Akap*1^-/-^, C57BL/6 background) and *Akap1* heterozygous mice (*Akap*^+/-^, C57BL/6 background) were kindly donated by McKnight G. S. and have been previously described ([@B32]; [@B40]). *Siah2* knockout mice (*Siah2*^-/-^, C57BL/6 background) were kindly donated by Bowtell D. Wild-type (*wt*, C57BL/6 background) *Akap*1^+/-^ and *Akap*1^-/-^ mice of either gender (8--9 weeks old) were included in the study and maintained under identical conditions of temperature (21 ± 1°C), humidity (60 ± 5%), and light/dark cycle, and had free access to normal mouse chow.

Mouse Model of Pressure Overload-Induced Cardiac Hypertrophy and Heart Failure
------------------------------------------------------------------------------

Pressure overload was induced in adult *Akap1*^+/-^, *Akap*1^-/-^, and *Siah2*^-/-^ mice and their *wt* littermates by transverse aortic constriction (TAC) as previously described ([@B18]; [@B3]). Briefly, mice were anesthetized by intraperitoneal injection of 0.1 ml/kg of mixture of 50% Tiletamine and 50% Zolazepam (Zoletil 100) and Xylazine 5 mg/kg (Sigma-Aldrich) and a surgical suture was passed across the aortic arch between left common carotid artery and innominate artery. Another group of animals underwent a left thoracotomy without aortic constriction (sham). Mice from all the groups were sacrificed 1 week (1w) after surgery to perform molecular analyses. Only TAC animals with systolic pressure gradients \>40 mmHg were included in the study.

Transthoracic Echocardiography
------------------------------

Cardiac function was non-invasively monitored by transthoracic echocardiography using the Vevo 770 high-resolution imaging system equipped with a 30-MHz RMV-707B scanning head (Visual-Sonics, Toronto, ON, Canada) 1w after sham or TAC operation in mice of all genotypes as previously described ([@B18]; [@B36]).

Protein Extraction and Immunoblotting
-------------------------------------

Heart and cellular samples were homogenized in a buffer containing 150 mmol/L NaCl, 50 mmol/L Tris-HCl (pH 8.5), 2 mmol/L EDTA, 1% v/v NP-40, 0.5% w/v deoxycholate, 10 mmol/L NaF, 10 mM sodium pyrophosphate, 2 mmol/L PMSF, 2 heart leupeptin, 2 heart aprotinin, pH 7.4, using the program Protein_1 on a GentleMACS tissue Dissociator (Miltenyi Biotec; [@B19]; [@B13]). Protein concentration in all lysates was measured by using a dye-binding protein assay kit (Bio-Rad) and a SmartSpec Plus spectrophotometer (Bio-Rad) reading at a wavelength of 595 nm. Immunoblotting was performed by using commercially available antibodies: anti-Akt (rabbit polyclonal, Santa Cruz Biotechnology), anti-pAkt (Ser473, rabbit polyclonal, Cell Signaling), anti-cleaved Caspase-3 (rabbit polyclonal, Cell Signaling), anti-AKAP121 ([@B10]; rabbit polyclonal), anti-caspase-9 (rabbit polyclonal, Santa Cruz Biotechnology), anti-IDH2 (goat polyclonal, Santa Cruz Biotechnology), anti-phosphoPKA substrates (rabbit polyclonal, Cell Signaling), anti-GAPDH (mouse monoclonal, Santa Cruz Biotechnology), and anti-tubulin (mouse monoclonal, Sigma-Aldrich). Secondary antibodies were purchased from Amersham Life Sciences (GE Healthcare). Bands were visualized by enhanced chemiluminescence (ECL; Amersham Life Sciences) according to the manufacturer's instructions, and were quantified by using densitometry (Chemidoc, Bio-Rad). Each experiment and densitometric quantification was separately repeated at least three times.

RNA Isolation and Real-Time PCR
-------------------------------

Total RNA was prepared using TRIzol (Invitrogen, Eugene, OR, United States), according to the manufacturer's instruction. Oligo-dT first strand cDNA was synthesized using the SuperScript VILO cDNA Synthesis Kit (Invitrogen, Life technologies) according to the manufacturer's instructions. mRNA expression was determined in cardiac samples from different experimental groups by real-time quantitative PCR (RT-PCR) using a IQ-5 Multicolor Real-Time PCR Detection System (BIORAD). The primers used were: β-MHC: forward 5′-GAGACGACTGTGGCCTCC-3′, reverse 5′-GCATGATGGCGCCTGTCAG-3′; Collagen IA1: forward 5′-GGAGACAGGTCAGACCTGTGTG-3′, reverse 5′-CAGCTGGATAGCGACATCGGC-3′; Collagen III: forward 5′-ATATCAAACACGCAAGGC-3′, reverse 5′-GATTAAAGCAAGAGGAACAC-3′; Fibronectin: forward 5′- ACCGTGTCAGGCTTCCGG-3′, reverse 5′- ACGGAAGTGGCCGTGCTT-3′; and GAPDH: forward 5′-TGCAGTGGCAAAGTGGAGATT-3′, reverse 5′-TCGCTCCTGGAAGATGGTGAT-3′.

Mitochondria Isolation and Evaluation of Respiratory Parameters
---------------------------------------------------------------

Mitochondria were isolated from cardiac samples and respiration rate was detected on isolated mitochondria as previously described ([@B36]; [@B40]). Briefly, hearts were gently homogenized in a buffer containing 220 mM mannitol, 70 mM sucrose, 20 mM Tris⋅HCl, 1 mM EDTA, and 5 mM EGTA (pH 7.4) and then centrifuged at 8,000 *g* for 10 min at 4°C. The supernatant was further centrifuged and the mitochondrial pellet was either use for immunoblot analysis or to measure mitochondrial respiration ([@B36]; [@B40]).

Adult Ventricular Murine Myocytes Isolation
-------------------------------------------

Adult ventricular myocytes were isolated from murine adult hearts using a modified heart retrograde perfusion-based method. Briefly, mice were injected with heparin and anesthetized with an intraperitoneal injection of 0.1 ml/kg of mixture of 50% Tiletamine and 50% Zolazepam (Zoletil 100) and Xylazine 5 mg/kg (Sigma-Aldrich). The heart was quickly excised, and the aorta was cannulated for retrograde perfusion in a Langendorff apparatus at a constant flow rate of 1.5 ml/min at 37°C. The heart was perfused for 9--10 min with isolation buffer \[NaCl 120 mM, KCl 4.4 mM, MgCl~2~ 1 M, NaH~2~PO~4~ 1.2 mM, NaHCO~3~ 20 mM, glucose 5 mM, 2,3-butanedione monoxime (BDM) 1.25 mM, and taurine 5 mM, pH 7.4\], bubbling the isolation solution with 95% O~2~ -- 5% CO~2~, followed by digestion for 13 min with collagenase II (350 U/ml; Worthington) in isolation buffer. After digestion, myocytes were suspended in isolation buffer, filtered with a mesh (100 μm), gently spin down (300 g for 1 min), and resuspended for stepwise Ca^2+^ reintroduction from 25 μmol/L to 1.0 mmol/L. Myocytes were than lyzed in a buffer containing Tris 1 M, 1% v/v Nonidet P-40, NaCl 5 M, 10% w/v deoxycholate, NaVO~3~ 100 mM, and NaF 100 mM to extract protein as described above.

Histology
---------

Mouse heart specimens were fixed in 4% formaldehyde and embedded in paraffin. After de-paraffinization and re-hydratation, 4-μm-thick sections were prepared and mounted on glass slides. An even number of cardiac cross sections per group were stained with wheat germ agglutinin (WGA) or Picosirius red as previously described ([@B40]). Briefly, thin cardiac sections were analyzed using Nikon light microscope and NIS Elements Basic Research software (Nikon). For assessment of cardiomyocyte cross sectional area, mean area was evaluated by measuring 400--500 cells per heart (*n* = 4--5 animals/group). Fibrotic regions (6--8 fields/section, *n* = 4--5 animals/group) were measured as percent of collagen-stained area/total myocardial area and averaged using a computer-assisted image analysis software (Image J software, National Institutes of Health).

TUNEL Staining
--------------

Cardiac DNA nicks were assayed by an *in situ* Apoptosis Detection kit or ApopTag Fluorescein Direct *in situ* Apoptosis Detection kit (Chemicon) according to manufacturer's instructions as previously described ([@B19]; [@B40]). TUNEL staining was visualized by specific green fluorescence and nuclei by 4′-6-diamidino-2-phenylindole (DAPI). TUNEL-positive cardiomyocytes nuclei identified were normalized by total nuclei stained in the same sections by DAPI (*n* = 7--8 animals/group). An even numbers of slides were analyzed for each group.

Statistical Analysis
--------------------

All data presented are representative of three or more independent experiments and are expressed as mean ± SEM. Comparisons between two groups were performed using the unpaired Student's *t*-test. For experiments including three or more experimental groups, comparisons were made by one-way analysis of variance (ANOVA) or 2-way ANOVA, and *p* values shown indicate the effect of genotype response. Correction for multiple comparisons was made using the Student--Newman--Keuls method. A minimum value of *p* \< 0.05 was considered statistically significant. All statistical analyses were conducted with Prism statistical software.

Results
=======

*Akap1* Deletion Enhances Cardiac Hypertrophy After Transverse Aortic Constriction in Mice
------------------------------------------------------------------------------------------

We have previously demonstrated that myocardial levels of AKAP121 decrease in a rat model of LVH induced by ascending aortic banding ([@B33]), suggesting a role for this adaptor protein in the transmission of hypertrophic signals in the myocardium. However, the effects of *Akap1* genetic deletion on cardiac remodeling in response to pressure overload are currently unknown. Consistent with our previous results, AKAP121 cardiac levels were significantly decreased in *wt* mice subjected to 1w TAC compared to sham-operated littermates (**Figure [1A](#F1){ref-type="fig"}**), and these results were associated with the impairment of mitochondrial PKA signaling (Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}). Importantly, AKAP121 downregulation was also observed in adult ventricular myocytes isolated from *wt* TAC hearts (Supplementary Figure [S2](#SM1){ref-type="supplementary-material"}), demonstrating that AKAP121 downregulation in LVH occurs in cardiomyocytes. Interestingly, after TAC, both *Akap1*^+/-^ and *Akap1*^-/-^ mice exhibited a significant further increase in LVW/BW compared to *wt* TAC mice (**Figure [1B](#F1){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**), coupled with an increase in cardiomyocytes cross-sectional area measured by WGA staining (**Figure [1C](#F1){ref-type="fig"}**) and in β-myosin heavy chain (β-MHC) mRNA abundance (**Figure [1D](#F1){ref-type="fig"}**). No differences were found among the three different genotypes in cardiac interstitial fibrosis, measured by Picrosirius red staining (**Figure [2A](#F2){ref-type="fig"}**), as well as in the mRNA abundance of the most common fibrotic markers: collagen type I, type III, and fibronectin (**Figures [2B](#F2){ref-type="fig"}--[D](#F2){ref-type="fig"}**). Collectively, these data suggest that loss of *Akap1* exacerbates cardiac hypertrophy induced by pressure overload without affecting the fibrotic response.

![*Akap1* deficiency exacerbates pressure overload-induced cardiac hypertrophy. **(A)** Representative immunoblot (left) and densitometric analysis (right) of AKAP121 protein levels in hearts from sham (*n* = 5) and 1 week transverse aortic constriction (TAC 1w; *n* = 7) operated *wt, Akap1*^+/-^, and *Akap1*^-/-^ mice. GAPDH was used as control of loading sample (^∗^*p* \< 0.05 vs. *wt* sham). **(B)** Bar graphs showing cumulative data of left ventricular weight (LVW) to body weight (BW) 1 week after sham or TAC procedures in *wt, Akap1*^+/-^, and *Akap1*^-/-^ mice (^∗^*p* \< 0.05 vs. sham; ^§^*p* \< 0.05 vs. *wt* TAC 1w; *n* = 7 hearts/group). **(C)** (Left) Representative images of wheat germ agglutinin (WGA) staining of cardiac transversal sections from *wt, Akap1*^+/-^, and *Akap1*^-/-^ mice 1 week after sham or TAC procedure. DAPI was used as nuclei counterstaining. Scale bar: 20 μm. (Right) Bar graphs showing cumulative data of multiple independent experiments analyzing cardiomyocytes cross-sectional area (^∗^*p* \< 0.05 vs. sham; ^§^*p* \< 0.05 vs. *wt* TAC 1w; *n* = 5 hearts/group). **(D)** mRNA levels of β-myosin heavy chain (β-MHC) in cardiac samples from *wt, Akap1*^+/-^, and *Akap1*^-/-^ mice 1 week after sham or TAC procedure (^∗^*p* \< 0.05 vs. sham; *n* = 5 hearts/group).](fphys-09-00558-g001){#F1}

###### 

Echocardiographic and morphometric analysis in the different experimental groups of mice.

                         *wt*          *Akap1*^+/-^    *Akap1*^-/-^                                   
  ---------------------- ------------- --------------- -------------- ---------------- -------------- -----------------
  **Morphometry**                                                                                     
  BW (g)                 27.3 ± 1.4    23.0 ± 0.7\*    23.3 ± 0.8     23.6 ± 0.9       23.4 ± 1.1     23.0 ± 0.5
  LVW (mg)               84.9 ± 4.9    100.4 ± 5.9\*   73.6 ± 3.3     124.0 ± 4.4\*§   76.9 ± 7.0     99.6 ± 5.3\*\#
  HW (mg)                112.5 ± 7.0   131.8 ± 7.8     95.8 ± 4.7     154.6 ± 4.7\*§   105.8 ± 10.2   135.1 ± 7.3\*\#
  LVW/BW (mg/g)          3.1 ± 0.1     4.2 ± 0.2\*     3.1 ± 0.1      5.4 ± 0.2\*§     3.3 ± 0.2      5.7 ± 0.6\*§
  HW/BW (mg/g)           4.9 ± 0.1     5.6 ± 0.3\*     4.1 ± 0.1      6.6 ± 0.2\*      4.5 ± 0.3      5.9 ± 0.3\*
  **Echocardiography**                                                                                
  LVEDd (mm)             3.0 ± 0.1     3.1 ± 0.1       3.0 ± 0.1      4.0 ± 0.1\*§     3.2 ± 0.1      3.6 ± 0.1\*§
  LVESd (mm)             1.2 ± 0.1     1.6 ± 0.1\*     1.2 ± 0.1      2.7 ± 0.1\*§     1.3 ± 0.1      2.4 ± 0.2\*§
  IVS,d (mm)             0.7 ± 0.0     1.1 ± 0.0\*     0.8 ± 0.0      1.0 ± 0.0\*      0.8 ± 0.0      1.0 ± 0.0\*
  PW,d (mm)              0.8 ± 0.0     0.9 ± 0.0\*     0.8 ± 0.0      1.0 ± 0.0\*      0.8 ± 0.0      0.9 ± 0.1
  FS (%)                 60.6 ± 1.8    50.3 ± 2.3\*    60.0 ± 1.2     32.5 ± 2.8\*§    58.6 ± 2.3     33.5 ± 3.4\*§
  HR (bpm)               573 ± 11      583 ± 17        595 ± 30       584 ± 23         681 ± 19       661 ± 16

BW, body weight; LVW, left ventricle weight; HW, heart weight; LVEDd, left ventricular end-diastolic diameter; LVESd, left ventricular end-systolic diameter; IVS,d interventricular septum end-diastolic diameter; PW,d posterior wall end-diastolic diameter; FS, fractional shortening; HR, heart rate (
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![Loss of *Akap1* does not affect cardiac fibrosis response after pressure overload. **(A)** (Left) Representative images of Picrosirius red staining of cardiac transversal sections from *wt, Akap1*^+/-^, and *Akap1*^-/-^ mice 1 week after sham or TAC procedure. Scale bar: 40 μm. (Right) Bar graphs showing cumulative data of multiple independent experiments analyzing percentage of fibrosis (^∗^*p* \< 0.05 vs. sham *wt*; *n* = 5 hearts/group). mRNA levels of collagen I (Col1A1, **B**), collagen III (Col3; **C**), and fibronectin **(D)** in cardiac samples from *wt, Akap1*^+/-^, and *Akap1*^-/-^ mice 1 week after sham or TAC procedure (^∗^*p* \< 0.05 vs. sham; *n* = 5 hearts/group).](fphys-09-00558-g002){#F2}

Genetic Deletion of *Akap1* Precipitates Heart Failure Induced by Pressure Overload
-----------------------------------------------------------------------------------

Chronic pressure overload inevitably leads to impairment in LV systolic function and ultimately HF ([@B18]; [@B41]). As expected, after 1w TAC, *wt* mice exhibited a mild but significant reduction in % FS compared to sham-operated animals (**Figures [3A,B](#F3){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**). Reduction in % FS in *wt* mice was mainly due to the increase in LV end-systolic diameter (LVESd, **Figure [3C](#F3){ref-type="fig"}**) without significant changes in LV end-diastolic diameter (LVEDd, **Figure [3D](#F3){ref-type="fig"}**). In *Akap1*^+/-^ and *Akap1*^-/-^ mice, TAC operation caused a significant further decrease of % FS compared to TAC *wt* mice (**Figures [3A,B](#F3){ref-type="fig"}**). Reduction in % FS observed in *Akap1*^+/-^ and *Akap1*^-/-^ after TAC, resulted by increase in both LVESd and LVEDd (**Figures [3C,D](#F3){ref-type="fig"}**). The differences in LV systolic function between *wt* and *Akap1*-deficient mice after stress suggest that *Akap1* plays an important role in the progression toward HF after chronic pressure overload.

![Genetic deletion of *Akap1* accelerates the progression toward heart failure in TAC mice **(A)**. Representative left ventricular (LV) M-mode echocardiographic tracings from *wt, Akap1*^+/-^ and *Akap1*^-/-^ mice after sham or TAC 1w procedures (*n* = 7 mice/group). Cumulative data of % fractional shortening **(B)**, left ventricular end-systolic diameter (LVESd; **C**) and left ventricular end-diastolic diameter (LVEDd; **D**) in *wt, Akap1*^+/-^ and *Akap1*^-/-^ mice 1 week after sham or TAC procedure (^∗^*p* \< 0.05 vs. sham; ^§^*p* \< 0.05 vs. TAC 1w *wt*; *n* = 5 hearts/group).](fphys-09-00558-g003){#F3}

Increased Apoptosis and Blunted *Akt* Activation in *Akap1*^-^*^/^*^-^ Hearts After Pressure Overload
-----------------------------------------------------------------------------------------------------

Reduction in LV systolic function is dependent on loss of contractile cellular elements, since cardiomyocytes apoptosis occurs in the context of pressure overload stress. Thus, we next investigated the presence of apoptosis in *wt* and *Akap1*^-/-^ TAC hearts. Consistently with cardiac functional data presented above, myocardial levels of cleaved caspase-3, a well-known effector of apoptosis, increased after 1w of TAC in *wt* mice (**Figure [4A](#F4){ref-type="fig"}**). Strikingly, in *Akap1*^-/-^ hearts, we observed a significant further increase in cleaved caspase-3 myocardial levels compared to *wt* animals (**Figure [4A](#F4){ref-type="fig"}**). To confirm that increased apoptosis was present in *Akap1*^-/-^ hearts, we quantified the number of TUNEL-positive nuclei in myocardial sections from *Akap1*^-/-^ and *wt* mice. Consistent with previous data, after TAC, the % number of TUNEL-positive cells was significantly higher in *Akap1*^-/-^ hearts compared to *wt* littermates (**Figure [4B](#F4){ref-type="fig"}**). In order to determine the contribution of mitochondrial-dependent apoptotic pathways in the absence of *Akap1*, we evaluated the levels of the mitochondrial apoptotic protein caspase-9 in cardiac lysates from *wt* and *Akap1*^-/-^ mice. Interestingly, *Akap1*^-/-^ hearts exhibited a significant increase in caspase-9 cleavage compared to *wt* hearts after both sham and TAC procedure (Supplementary Figure [S3](#SM1){ref-type="supplementary-material"}). These data indicate that loss of *Akap1*^-/-^ increased the susceptibility to pressure overload-induced apoptosis, which is, at least in part, dependent by activation of mitochondrial pro-apoptotic pathways.

![Increased cardiac apoptosis and lack of Akt activation in *Akap1*^-/-^ mice after TAC. **(A)** Representative immunoblot (left) and densitometric analysis (right) of cleaved caspase-3 protein levels in *wt* and *Akap1*^-/-^ hearts 1 week after sham or TAC procedure (^∗^*p* \< 0.05 vs. sham; ^§^*p* \< 0.05 vs. *wt* TAC 1w; *n* = 5 hearts/group). Tubulin was used as control of loading sample. **(B)** (Left) Representative DAPI and TUNEL staining of cardiac sections from *wt, Akap1*^+/-^, and *Akap1*^-/-^ mice 1 week after sham or TAC procedure. Positive nuclei appear green. Scale bar: 20 μm. (Right) Bar graphs showing cumulative data of multiple independent experiments evaluating TUNEL-positive cells (^∗^*p* \< 0.05 vs. sham; ^§^*p* \< 0.05 vs. *wt* TAC 1w; *n* = 5 hearts/group). **(C)** Representative immunoblot (left) and densitometric analysis (right) of Akt Ser 473 phosphorylation (pAkt) and Akt in *wt* and *Akap1*^-/-^ hearts 1 week after sham or TAC procedure. GAPDH was used as control of loading sample (^∗^*p* \< 0.05 vs. sham; ^§^*p* \< 0.05 vs. *Akap1*^-/-^ TAC 1w; *n* = 5 hearts/group).](fphys-09-00558-g004){#F4}

Activation of Akt-dependent protective signals is a hallmark of HF ([@B14]). Recently, we have shown that loss of *Akap1* in vascular endothelial cells (ECs) blunts ischemia-induced Akt activation resulting in dysfunctional behavior of ECs ([@B39]). Given the fact the *Akap1*^-/-^ mice have an accelerated progression toward HF after pressure overload and that *Akap1*^-/-^ hearts are more susceptible to stress-induced apoptosis, we hypothesized that loss of cardioprotective signals from Akt might play a role in this context. Activation of Akt (Ser473 phosphorylation) occurred in *wt* hearts after TAC (**Figure [4C](#F4){ref-type="fig"}**), whereas *Akap1*^-/-^ hearts exhibited a blunted activation of Akt in response to pressure overload (**Figure [4C](#F4){ref-type="fig"}**). The absence of Akt activation together with the enhanced apoptotic rate observed in *Akap1*^-/-^ hearts suggests that both mechanisms might act in concert to determine the impaired cardiac function of *Akap1*^-/-^ mice after pressure overload.

*Siah2* Deletion Prevents AKAP121 Degradation After Pressure Overload
---------------------------------------------------------------------

Others and we have previously demonstrated that the absence of *Siah2* prevents hypoxia-induced AKAP121 degradation ([@B40]; [@B26]). To investigate whether *Siah2* deletion might prevent AKAP121 degradation in response to pressure overload, *Siah2*^-/-^ mice underwent the TAC procedure. One week after surgery, downregulation of AKAP121 cardiac levels was significantly inhibited in *Siah2*^-/-^ mice compared to *wt* littermates (**Figure [5A](#F5){ref-type="fig"}**). Interestingly, *Siah2*^-/-^ mice exhibited the same extent of cardiac hypertrophy estimated by LVW/BW compared to *wt* controls (**Figure [5B](#F5){ref-type="fig"}**), as well as similar deterioration of cardiac function investigated by means of FS% (**Figure [5C](#F5){ref-type="fig"}**), LVESd (**Figure [5D](#F5){ref-type="fig"}**), and LVEDd (**Figure [5E](#F5){ref-type="fig"}**).

![Siah2 deficiency prevents AKAP121 degradation after TAC. **(A)** Representative immunoblot (left) and densitometric analysis (right) of AKAP121 protein levels in *wt* and *Siah2*^-/-^ hearts 1 week after sham or TAC procedure. GAPDH was used as control of loading sample (^∗^*p* \< 0.05 vs. *wt* sham). **(B)** Bar graphs showing cumulative data of LVW/ BW 1 week after sham or TAC procedures in *wt* and *Siah2*^-/-^ mice (^∗^*p* \< 0.05 vs. sham; *n* = 6 hearts/group). Cumulative data of % fractional shortening **(C)**, left ventricular end-systolic diameter (LVESd; **D**), and left ventricular end-diastolic diameter (LVEDd; **E**) in *wt* and *Siah2*^-/-^ mice 1 week after sham or TAC procedure (^∗^*p* \< 0.05 vs. sham; *n* = 6 hearts/group).](fphys-09-00558-g005){#F5}

Discussion
==========

In the present study, we demonstrate for the first time that *in vivo* genetic deletion of *Akap1* exacerbates pressure overload-induced cardiac hypertrophy development and accelerates the progression toward HF after TAC in mice. These abnormalities in *Akap1*^-/-^ mice are associated to an increased rate of cardiac apoptosis and lack of activation of Akt-dependent cardioprotective signals. These results extend the knowledge about *Akap1* in cardiac biology, and confirm its role as a critical mediator of pathological LVH.

Cardiac hypertrophy is the first, general response of the heart to physiological or pathological loads ([@B15]; [@B22]). However, while cardiac adaptations induced by physiological stimuli such as exercise do not result in HF, cardiac overload induced by pathological stimuli, such as chronic hypertension or heart valve disease, eventually leads to cardiac dysfunction ([@B5]; [@B24]; [@B34]). Abnormalities in cAMP/PKA signaling are a hallmark of pathological LVH and HF ([@B35]). AKAPs scaffold proteins compartmentalize PKA activity into subcellular domains (e.g., mitochondria), thus allowing a tight-controlled spatial and temporal regulation of cellular responses ([@B20]; [@B32]).

The transmission of cAMP signaling to mitochondria is reached by a family of mitoAKAPs that have been shown to play an important role in cardiac response to stress ([@B33]; [@B16]). In particular, others and we have shown that AKAP121 is critical for cardiomyocytes response to ischemic injury ([@B26]; [@B40]). Genetic deletion of *Akap1* results in larger infarct size, worse LV systolic function, and increased mortality after myocardial infarction ([@B40]). Although the absence of *Akap1* was associated to increased mitochondrial dysfunction, mitophagy, and ROS production, the specific mechanisms by which loss of *Akap1* results in worse post-ischemic cardiac remodeling remain elusive. More recently, we have shown that AKAP121 also regulates ECs behavior in response to ischemia through Akt signaling ([@B39]). In ECs, lack of *Akap1* affects multiple cellular functions and results in reduced Akt activation upon angiogenic stimuli or hypoxia ([@B39]). In the present investigation, we demonstrated that in response to pressure overload, deletion of *Akap1* results in exacerbated LVH in the absence of Akt activation, confirming in a different experimental model of cardiovascular disease that the presence of AKAP121 is necessary to achieve Akt activation in response to stress.

A previous study has shown that AKAP121 acts as a repressor of cardiomyocytes hypertrophy ([@B1]). Silencing of AKAP121 *in vitro* resulted in increased cardiomyocytes cell size in the absence of any pro-hypertrophic stimulus ([@B1]). Although our data confirm the role of AKAP121 as a brake of cardiomyocytes growth, others and we repetitively observed the absence of any basal cardiac alterations in *Akap1*^-/-^ mice ([@B32]; [@B40], [@B39]). In-depth characterization of cardiac structure and function in *Akap1*^-/-^ mice revealed that absence of *Akap1* did not cause LVH and HF over time. In addition, we have previously demonstrated that *in vivo* administration of synthetic peptides displacing AKAP121 from mitochondria increased cardiac ROS and apoptotic cell death, but is was not sufficient to induce cardiac hypertrophy, even if we observed increased nuclear localization of nuclear factor of activated T-cells (NFAT), the main effector of the calcineurin-dependent pro-hypertrophic signaling pathway ([@B33]). However, when subjected to pressure overload, *Akap1*-deficient mice develop a more robust hypertrophic response and an accelerated progression toward HF, confirming that *Akap1* acts as a repressor of cardiomyocytes hypertrophy. The fact that, only if stressed, *Akap1*^-/-^ hearts exhibit pronounced cardiac hypertrophy might be in contrast with the previous notion that knockdown of AKAP121 *in vitro* affects *per se* cardiomyocyte size. However, this apparent discrepancy can be explained by the fact that, *in vivo*, Rab32, a mitochondria-targeted AKAP-like protein, might exert compensatory effects in the absence of *Akap1* ([@B2]; [@B7]). The pivotal role of AKAP121 in the regulation of HF development was also confirmed by the evidence that while *Akap1*-deficient mice underwent rapid deterioration of cardiac function in response to pressure overload, and this process was not observed in *Siah2*-deficient mice.

The absence of *Akap1* has been variously associated with increased ROS production and mitochondrial dysfunction in several models of cardio- and cerebrovascular diseases as well as in cancer ([@B21]; [@B43]; [@B40]; [@B38]). For example, despite no basal differences were found in mitochondrial respiration between *Akap1*^-/-^ and *wt* hearts, following myocardial infarction, *Akap1*^-/-^ mice exhibited increase levels of cardiac ROS and more prominent alterations in mitochondrial morphology compared to *wt* controls ([@B40]). After 1w-TAC, no differences were observed between *Akap1*^-/-^ and *wt* mice in cardiac mitochondrial respiratory function (Supplementary Figure [S4](#SM1){ref-type="supplementary-material"}). However, we cannot exclude that alterations in mitochondrial function might occur at a later time point in *Akap1*^-/-^ hearts in the context of pressure overload. These results suggest that mitochondrial morphological and functional alterations induced by the absence of *Akap1* might be influenced by the nature and/or duration of stress that triggers cardiac dysfunction.

As mentioned above, the absence of *Akap1* leads to lack of Akt activation in hypertrophic hearts, and we speculate that Akt could mediate the effects of *Akap1* deletion on hypertrophic growth. Akt is at the crossroad of signaling pathways regulating cardiac growth and contractile function ([@B4]; [@B14]). Being downstream of insulin/insulin-like growth factor (IGF), Akt activation has been associated to physiological LVH development ([@B17]). However, Akt phosphorylation has also been found increased in pathological LVH as an initial response to afterload stress ([@B14]). Therefore, Akt activation in TAC has been recognized as a pro-survival adaptation signal, required for the activation of protein synthesis in cardiomyocytes ([@B29]; [@B23]; [@B9]). Consistent with this notion, *Akap1*^-^*^/^*^-^ mice subjected to TAC exhibited increased cardiac cell death and an accelerated progression toward HF coupled with lack of Akt activation. A number of signaling molecules are placed downstream of Akt. Among these, the mechanistic target of rapamycin (mTOR) plays a central role in cardiomyocyte hypertrophy ([@B31]). Recently, *Akap1* has been shown to control mTOR regulating cancer cells growth ([@B38]). However, the mechanisms by which *Akap1* influences Akt/mTOR signaling pathway remain poorly understood. Akt localizes to diverse sub-cellular compartments, including mitochondria, where it contributes to phosphorylation of key mitochondrial targets ([@B6]; [@B30]; [@B28]). The absence of *Akap1* leads to reduction in Akt phosphorylation in LVH as well as in vascular dysfunction ([@B39]), suggesting that mitoAKAPs might also contribute to Akt subcellular distribution to promote cell survival. Hence, it is possible to hypothesize that mitoAKAPs might act as a signaling platform contributing to stabilize Akt mitochondrial localization to preserve mitochondrial function and promote survival. Further studies will be necessary to clarify the precise mechanism(s) by which loss of *Akap1* prevents Akt activation upon different stressors.

Conclusion
==========

Our findings support the critical role of mitoAKAPs in cardiac responses to pressure overload, identifying Akt as potential mediator of their anti-hypertrophic effects.

Author Contributions
====================

GS, NB, RP, FC, VT, AFr, SD'A, GG, LR, DB, and AG performed the experiments and made the analyses. GS and CP wrote the manuscript. AL, AFe, and GE contributed to the experimental design and manuscript preparation. CP conceived the project.

Conflict of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** This work was supported, in part, by Ministero della Salute (GR-1004 2009-1596220), Ministero dell'Istruzione, Università e Ricerca Scientifica (RBFR124FEN; 2015583WMX) grants to CP and Associazione Italiana Ricerca sul Cancro grant (IG-15264) to AFe. This research was also carried out in the frame of Program STAR, financially supported by University of Naples Federico II (Unina) and Compagnia di San Paolo (grant to CP).

We gratefully thank Prof. Stanley McKnight (Department of Pharmacology, University of Washington, United States) for kindly providing us with *Akap1*^-/-^ mice and Prof. David Bowtell Ph.D. (Peter MacCallum Cancer Centre, Melbourne, Australia) for kindly providing us with *Siah2*^-/-^ mice.

Supplementary Material
======================

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fphys.2018.00558/full#supplementary-material>

###### 

Click here for additional data file.

[^1]: Edited by: Pasquale Pagliaro, Università degli Studi di Torino, Italy

[^2]: Reviewed by: Alfredo Criollo, Universidad de Chile, Chile; Wang Wang, University of Washington, United States

[^3]: This article was submitted to Clinical and Translational Physiology, a section of the journal Frontiers in Physiology
